眾生藥業(002317.SZ):仲強藥業100%股權已變更至上海雍威名下 公司不再持其股權
格隆匯 9 月 17日丨眾生藥業(002317.SZ)公佈,公司於2020年8月23日召開第七屆董事會第六次會議審議通過了《關於轉讓子公司股權的議案》,同意公司將持有的廣東仲強藥業有限公司(以下簡稱“仲強藥業”)100%股權以人民幣9000萬元轉讓給上海雍威生物科技有限公司(以下簡稱“上海雍威”)。
近日,仲強藥業完成相關工商變更手續,公司持有的仲強藥業100%股權變更至上海雍威名下,公司不再持有仲強藥業股權,自2020年9月起,仲強藥業不再納入公司合併報表範圍內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.